stoxline Quote Chart Rank Option Currency Glossary
  
89bio, Inc. (ETNB)
10.57  -0.15 (-1.4%)    02-14 16:00
Open: 10.85
High: 11
Volume: 1,738,906
  
Pre. Close: 10.72
Low: 10.425
Market Cap: 1,541(M)
Technical analysis
2025-02-14 4:47:51 PM
Short term     
Mid term     
Targets 6-month :  13.82 1-year :  16.15
Resists First :  11.84 Second :  13.82
Pivot price 10.33
Supports First :  8.22 Second :  5.98
MAs MA(5) :  10.89 MA(20) :  9.43
MA(100) :  8.3 MA(250) :  8.91
MACD MACD :  0.9 Signal :  0.8
%K %D K(14,3) :  74.5 D(3) :  80.9
RSI RSI(14): 62.3
52-week High :  16.62 Low :  5.98
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ETNB ] has closed below upper band by 43.9%. Bollinger Bands are 53.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.01 - 11.1 11.1 - 11.16
Low: 10.24 - 10.34 10.34 - 10.4
Close: 10.44 - 10.59 10.59 - 10.69
Company Description

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Headline News

Thu, 13 Feb 2025
89bio, Inc. (NASDAQ:ETNB) Shares Sold by abrdn plc - MarketBeat

Sat, 08 Feb 2025
ETNB - 89bio, Inc. Latest Stock News & Market Updates - StockTitan

Thu, 06 Feb 2025
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Simply Wall St

Thu, 06 Feb 2025
Inside 89bio's Latest Executive Compensation Move: 163K Share Options Granted - StockTitan

Thu, 06 Feb 2025
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Yahoo Finance

Tue, 04 Feb 2025
Wolfe Research Initiates Coverage of 89bio (ETNB) with Outperform Recommendation - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 139 (M)
Shares Float 68 (M)
Held by Insiders 0.6 (%)
Held by Institutions 89.6 (%)
Shares Short 8,350 (K)
Shares Short P.Month 6,940 (K)
Stock Financials
EPS -2.97
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.55
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -41.4 %
Return on Equity (ttm) -73.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.19
Qtrly Earnings Growth 0 %
Operating Cash Flow -281 (M)
Levered Free Cash Flow -181 (M)
Stock Valuations
PE Ratio -3.58
PEG Ratio 0
Price to Book value 2.96
Price to Sales 0
Price to Cash Flow -5.25
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android